Jeffrey Clark, MD
Urology · Brookhaven, MSNPI 1376643247
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 154 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $661 and has fallen 62.9% since, to $245 in 2025. That places this record below the midpoint for urology clinicians in MS, where the typical reported total is $3,535.
Across 154 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$463
- Bayer$415
- Johnson & Johnson$206
- Tolmar Pharmaceuticals, Inc.$140
- AbbVie$123
- Procept Biorobotics Corporation$102
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,501100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 29 | $463 |
| Bayer | 25 | $415 |
| Johnson & Johnson | 22 | $206 |
| Tolmar Pharmaceuticals, Inc. | 9 | $140 |
| AbbVie(2 entities) | 10 | $123 |
| Procept Biorobotics Corporation | 3 | $102 |
| Urovant Sciences Inc | 6 | $96 |
| Ferring Pharmaceuticals Inc. | 5 | $81 |
| Olympus America Inc. | 3 | $75 |
| Cook Medical LLC | 2 | $73 |
| Urogen Pharma, Inc. | 3 | $69 |
| Sumitomo Pharma America, Inc. | 4 | $62 |
| Boston Scientific | 2 | $61 |
| Dendreon Pharmaceuticals LLC | 3 | $58 |
| Tolmar, Inc. | 3 | $57 |
| Coloplast | 4 | $50 |
| Teleflex LLC | 2 | $48 |
| Amgen | 3 | $41 |
| Myriad Genetic Laboratories, Inc. | 2 | $40 |
| Mission Pharmacal Company | 2 | $33 |
| Progenics Pharmaceuticals, Inc. | 1 | $31 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
| Accord Healthcare, Inc. | 1 | $19 |
| Hollister Incorporated | 1 | $17 |
| Axonics, Inc. | 1 | $17 |
| Myovant Sciences Inc. | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| Acerus Pharmaceuticals Corporation | 1 | $15 |
| Dentsply IH Inc. | 1 | $15 |
| Ambu Inc. | 1 | $14 |
| Photocure Inc | 1 | $12 |
| Pfizer | 1 | $12 |
How this compares
$2,501 in reported general payments places this provider in the 40th percentile of 94 urology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 219 | $114,250 |
| GemtesaVibegron | 115 | $68,544 |
| Tamsulosin Hcl | 1,350 | $13,043 |
| Finasteride | 575 | $6,716 |
| Trimethoprim | 126 | $5,807 |
| Potassium Citrate ErPotassium Citrate | 137 | $5,292 |
| Solifenacin Succinate | 246 | $5,254 |
| Oxybutynin Chloride ErOxybutynin Chloride | 419 | $5,247 |
| Estradiol | 57 | $3,940 |
| Testosterone Cypionate | 90 | $3,816 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 161 | $2,998 |
| Bicalutamide | 76 | $2,735 |
| Ciprofloxacin Hcl | 569 | $2,632 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 19 | $2,217 |
| Oxybutynin Chloride | 104 | $1,113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $463 | $114,250219 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $62 | $68,544115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 94 urology providers in Mississippi.
Other urology in Brookhaven
- Joel DuffBrookhaven$3K
- Sean DouglasHattiesburg$40K
- Robert HollabaughSouthaven$17K
- Kristopher WhiteheadTupelo$17K
- Harold BlalockJackson$15K
- Jon PoseyTupelo$13K
- Paul FarabaughTupelo$13K
- Clarance FarmerTupelo$12K
- Patrick DailyJackson$12K
- Kaitlen SchexnayderHattiesburg$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.